Allstate Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Allstate Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$1.24M	Buy	+5,228	New	+$1.12M	0.04%	302

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Allstate Investment Management's ALNY Position: Q4 2022 in Review

Allstate Investment Management opened a new position in Alnylam Pharmaceuticals (ALNY) in Q4 2022: 5,228 shares worth $1.24M. The stake represents 0.04% of the portfolio and ranks #302 among its holdings.

487 funds tracked by Wall St. Rank hold ALNY as of Q4 2022.

Allstate Investment Management held 5,228 shares of Alnylam Pharmaceuticals worth $1.24M as of Q4 2022.
Alnylam Pharmaceuticals was a new Allstate Investment Management position in Q4 2022.
Alnylam Pharmaceuticals made up 0.04% of Allstate Investment Management's portfolio in Q4 2022, its #302 holding.
487 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2022.

Based on Allstate Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.